Fig. 1 · Structure

Documents & Downloads

LY2811376

Cat. No. A11776 CAS 1194044-20-6

BACE1 inhibitor

LY2811376 is the first orally available non-peptidic BACE1 inhibitor that produces profound Aβ-lowering effects in animals.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
BACE1 239 nM-249 nM
Aβ EC50 ~300 nM

Cellular Effect

Cell Line Activity Value Description Reference
H4 IC50 0.27 μM Inhibition of BACE1 in human H4 cells expressing APP751 Swedish mutant assessed as inhibition of amyloid beta 40 or amyloid beta 42 production incubated for 19 hrs by microplate reader analysis [PMID: 26985314]
HEK293 IC50 0.239 μM Inhibition of human BACE1 (1 to 460 residues) expressed in HEK293 cells using mcaFRET peptide as substrate after 20 hrs by FRET assay [PMID: 31786008]
HEK293 IC50 0.24 μM Inhibition of IgG1 Fc-fused human recombinant BACE1 (1 to 460 residues) expressed in HEK293 cells using methylcoumarin peptide harboring Swedish mutant as substrate incubated for 20 hrs by FRET assay [PMID: 26985314]
HEK293 IC50 0.3 μM Inhibition of BACE-1 in HEK293 cells expressing human APP751 cDNA harboring N670L671 mutation pretreated for 2 hrs followed by measuring after 2 hrs by sandwich ELISA [PMID: 28749667]
HEK293 EC50 300 nM Inhibition of BACE1 in HEK293 cells expressing APPswedish mutant assessed as inhibition of amyloid beta production by ELISA [PMID: 24704031]

LY2811376 Research Summary

This section summarizes 4 in vivo studies of LY2811376 from 3 published references.

LY2811376 In Vivo Studies

Daily LY2811376 treatment was associated with muscle spindle loss in the tibialis anterior muscle of wild-type and heterozygous Bace1 mutant animals compared with corresponding vehicle-treated groups. In aged wild-type mice, oral LY2811376 reduced hippocampal sAPPβ levels compared with vehicle. Proteomic analysis showed that LY2811376 did not alter mouse plasma sVEGFR3 compared with vehicle treatment. In the inverted grid test, LY2811376-treated wild-type mice lost their footing faster than vehicle-treated animals. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Muscle spindle loss in treated animals

Animal study · Adult (P180) wild type [1]

Adult wild-type animals received LY2811376 daily at 100 μg/g of body weight/day for 29 consecutive days. Quantification in the tibialis anterior muscle showed loss of 40% of muscle spindles in wild-type and heterozygous Bace1 mutant animals compared with corresponding vehicle-treated groups.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Quantification of muscle spindles in the tibialis anterior musclemuscle spindle number loss of 40% of muscle spindles[1]

Conditions shared by the study groups

Treatment course
daily with Ly2811376 at a dose of 100 μg/g of body weight/day for 29 consecutive days
Vehicle
pharmasolve (ISP technologies Inc), and aliquots were diluted 1/16 in corn oil
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
LY2811376 100 μg/g of body weight/daycorresponding vehicle-treated groupsloss of 40% of muscle spindles in wild type and heterozygous Bace1 mutant animals, compared to corresponding vehicle-treated groups[1]
LY2811376 100 μg/g of body weight/day
Model: Adult (P180) wild type
Reported limits: Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: LY2811376

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Bace1 activity is required to sustain muscle spindles and to maintain motor coordination (S20, S22); Materials and methods > Bace1 inhibition in adult mice (S120, S121); Figure 2 legend (S199)

Quantification of muscle spindles in the tibialis anterior muscle: Quantification of muscle spindles in the tibialis anterior muscle; comparator: corresponding vehicle-treated groups — Results > Bace1 activity is required to sustain muscle spindles and to maintain motor coordination (S22); Figure 2 legend (S199)

LY2811376 100 μg/g of body weight/day · Results > Bace1 activity is required to sustain muscle spindles and to maintain motor coordination (S22); Materials and methods > Bace1 inhibition in adult mice (S121)

Reduced Hippocampal sAPPβ Levels in Aged Wild-Type Mice

Animal study · aged wild‐type C57BL/6 mice; 18–20 months; aged: n = 5 [2]

Aged wild-type mice received the study compound at 100 mg/kg body weight by oral gavage. At 12 h after treatment, hippocampal sAPPβ levels normalized with β-actin were reduced compared with vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
sAPPβ levels normalized with β‐actinReported result reducing the levels of sAPPβ in the hippocampus; ***p < 0.001[2]

Conditions shared by the study groups

Route
oral gavage
Treatment course
12 h after the treatment
Vehicle
10% DMSO, 40% PEG300, 5% Tween‐80, and 45% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
LY2811376 100 mg/kg body weightvehiclereducing the levels of sAPPβ in the hippocampus; ***p < 0.001[2]
LY2811376 100 mg/kg body weight
Model: aged wild‐type C57BL/6 mice; 18–20 months; aged: n = 5
Methods and source locations

Compound reported in the paper: LY2811376

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Age‐related increase in βAPP processing contributes to higher GluN2B synaptic contribution (S52); METHODS > BACE1 inhibitor (S66, S67, S68); FIGURE 5 legend (S229, S235)

sAPPβ levels normalized with β‐actin: sAPPβ levels normalized with β‐actin; comparator: vehicle — RESULTS > Age‐related increase in βAPP processing contributes to higher GluN2B synaptic contribution (S52); FIGURE 5 legend (S235)

LY2811376 100 mg/kg body weight · RESULTS > Age‐related increase in βAPP processing contributes to higher GluN2B synaptic contribution (S52); METHODS > BACE1 inhibitor (S67); FIGURE 5 legend (S229, S235)

Treatment Did Not Alter Plasma sVEGFR3 in Mice

Animal study · mice (n = 13, treated; n = 14, veh) [3]

Mice received treatment at 100 mg/kg, with vehicle-treated mice as controls. Proteomic analysis of murine plasma showed that treatment did not alter sVEGFR3.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
proteomic analysis of murine plasmaReported result did not alter sVEGFR3 in mouse plasma[3]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
LY2811376 100 mg/kgvehicle-treated micedid not alter sVEGFR3 in mouse plasma[3]
LY2811376 100 mg/kg
Model: mice (n = 13, treated; n = 14, veh)
Reported limits: Not stated in the sentences used: route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: LY2811376

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > sVEGFR3 is a pharmacodynamic activity marker for BACE2 in vivo. (S76, S77); Figure 6 legend (S265)

proteomic analysis of murine plasma: proteomic analysis of murine plasma; comparator: vehicle-treated mice — Results > sVEGFR3 is a pharmacodynamic activity marker for BACE2 in vivo. (S77); Figure 6 legend (S265)

LY2811376 100 mg/kg · Results > sVEGFR3 is a pharmacodynamic activity marker for BACE2 in vivo. (S76, S77)

Inverted grid performance in treated wild-type mice

Animal study · wild-type mice [1]

Wild-type mice received LY2811376 daily at 100 μg/g of body weight/day for 29 consecutive days. In the inverted grid test, treated animals lost their footing 3–4 times faster than vehicle-treated animals.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
inverted grid testgrip ability lost their footing 3–4 times faster[1]

Conditions shared by the study groups

Treatment course
daily with Ly2811376 at a dose of 100 μg/g of body weight/day for 29 consecutive days
Vehicle
pharmasolve (ISP technologies Inc), and aliquots were diluted 1/16 in corn oil
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
LY2811376 100 μg/g of body weight/dayanimals treated with the vehicleanimals treated with a Bace1 inhibitor lost their footing 3–4 times faster than animals treated with the vehicle[1]
LY2811376 100 μg/g of body weight/day
Model: wild-type mice
Reported limits: Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: LY2811376

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Bace1 activity is required to sustain muscle spindles and to maintain motor coordination (S26); Materials and methods > Bace1 inhibition in adult mice (S120, S121); Figure 2 legend (S200)

inverted grid test: inverted grid test; comparator: animals treated with the vehicle — Results > Bace1 activity is required to sustain muscle spindles and to maintain motor coordination (S26); Figure 2 legend (S200)

LY2811376 100 μg/g of body weight/day · Results > Bace1 activity is required to sustain muscle spindles and to maintain motor coordination (S26); Materials and methods > Bace1 inhibition in adult mice (S121)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1194044-20-6
Applications BACE1 inhibitor
Formula C15H14F2N4S
Molecular Weight 320.4
SMILES
C[C@]1(CCSC(=N1)N)C2=C(C=C(C(=C2)C3=CN=CN=C3)F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 16 mg/mL (49.94 mM)
Water Insoluble
Ethanol 63 mg/mL (196.65 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% PEG400+0.5% Tween80+5% propylene glycol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

LY2811376 Research References

  1. [1] Cheret C, Willem M, Fricker FR, et al. Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles. EMBO J (2013). PMID: 23792428 DOI: 10.1038/emboj.2013.146 Source material
  2. [2] Rajão-Saraiva J, Dunot J, Ribera A, et al. Age-dependent NMDA receptor function is regulated by the amyloid precursor protein. Aging Cell (2023). PMID: 36704841 DOI: 10.1111/acel.13778 Source material
  3. [3] Schmidt A, Hrupka B, van Bebber F, et al. The Alzheimer's disease-linked protease BACE2 cleaves VEGFR3 and modulates its signaling. J Clin Invest (2024). PMID: 38888964 DOI: 10.1172/JCI170550 Source material

Added to your cart

View Cart Checkout
Loading...